Subgroup analyses indicated that STAT5B was particularly protective in lung cancers (lnHR = −0.5170; p = 0.0042) and hematologic malignancies (lnHR = −0.6988; p < 0.0001). The gene discussed is STAT5B; the disease is hematologic disorder.